Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia
ICD-10 F13.27 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia.
F13.27 refers to a condition characterized by a dependence on sedative, hypnotic, or anxiolytic substances, which leads to the development of persisting dementia as a direct consequence of substance use. This condition is marked by cognitive impairment that persists even after the cessation of substance use. Patients may exhibit memory deficits, impaired reasoning, and difficulties with executive function. The dementia is induced by the prolonged use of these substances, which can alter brain chemistry and structure, leading to irreversible changes in cognitive function. Treatment typically involves a comprehensive approach that includes detoxification, cognitive rehabilitation, and psychosocial support. It is crucial for healthcare providers to recognize the signs of this condition early to implement appropriate interventions and support recovery.
Detailed history of substance use, mental status examinations, and cognitive assessments.
Patients presenting with cognitive decline and a history of sedative use.
Consideration of co-occurring mental health disorders and the need for a multidisciplinary approach.
Neurological evaluations, imaging studies, and cognitive testing results.
Patients with memory loss and neurological symptoms following sedative use.
Differentiating between substance-induced dementia and other neurodegenerative conditions.
Used to assess cognitive function in patients with suspected substance-induced dementia.
Detailed report of cognitive assessments and interpretations.
Psychiatrists and neurologists should collaborate on testing and interpretation.
Documenting cognitive impairment is crucial as it differentiates F13.27 from other forms of dementia and supports the need for specific treatment interventions.
